Canada announces new investments to boost the biomanufacturing industry
加拿大宣布新投資以推動生物製造產業發展
As of April 2026, Canada is cementing its position as a global leader in biotechnology.
截至2026年4月，加拿大正穩固其作為全球生物技術領導者的地位。
Through its Biomanufacturing and Life Sciences Strategy, the government has invested over $2.2 billion to ensure national health security and foster domestic innovation.
透過其「生物製造與生命科學策略」，政府已投入超過22億美元，以確保國家健康安全並促進國內創新。
These investments, ranging from major facility funding in Edmonton to new projects in Vancouver, aim to move Canada from a state of emergency response toward lasting industrial resilience.
這些投資從埃德蒙頓的主要設施資助到溫哥華的新專案，旨在推動加拿大從緊急應對狀態轉向持久的工業韌性。
While new state-of-the-art facilities—like the Moderna mRNA hub in Quebec—are now producing essential medicines, a significant challenge remains: the talent gap.
雖然諸如位於魁北克的莫德納mRNA中心等最先進設施現正生產必需藥物，但仍存在一個重大挑戰：人才缺口。
By focusing on talent development, agile regulation, and strategic infrastructure, Canada is shifting its focus from quick fixes to becoming a self-reliant powerhouse in medical research.
藉由專注於人才培育、靈活監管與策略性基礎建設，加拿大正將焦點從快速解決方案轉向成為醫療研究領域自給自足的強國。
